HB Wealth Management LLC Purchases 7,892 Shares of Globus Medical, Inc. $GMED

Posted by Brenda Bartman on Sep 11th, 2026

HB Wealth Management LLC grew its position in Globus Medical, Inc. (NYSE:GMED – Free Report) by 108.2% during the 2nd quarter, HoldingsChannel reports. The firm owned 15,185 shares of the medical device company’s stock after purchasing an additional 7,892 shares during the quarter. HB Wealth Management LLC’s holdings in Globus Medical were worth $1,200,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in GMED. AQR Capital Management LLC grew its holdings in shares of Globus Medical by 45.9% in the 1st quarter. AQR Capital Management LLC now owns 22,510 shares of the medical device company’s stock valued at $1,622,000 after buying an additional 7,086 shares during the period. Integrated Wealth Concepts LLC increased its position in shares of Globus Medical by 33.0% in the 1st quarter. Integrated Wealth Concepts LLC now owns 4,375 shares of the medical device company’s stock valued at $320,000 after buying an additional 1,085 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Globus Medical by 38.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,649 shares of the medical device company’s stock worth $2,228,000 after buying an additional 8,540 shares during the period. Jones Financial Companies Lllp raised its stake in Globus Medical by 237.3% during the 1st quarter. Jones Financial Companies Lllp now owns 850 shares of the medical device company’s stock worth $62,000 after buying an additional 598 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in Globus Medical by 8.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 347,527 shares of the medical device company’s stock worth $25,439,000 after acquiring an additional 28,027 shares in the last quarter. 95.16% of the stock is owned by institutional investors.

Insider Transactions at Globus Medical

In other Globus Medical news, Director Stephen Zarrilli sold 25,000 shares of Globus Medical stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $87.04, for a total value of $2,176,000.00. Following the sale, the director directly owned 25,000 shares in the company, valued at approximately $2,176,000. The trade was a 50.00% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 18.38% of the company’s stock.

Globus Medical Stock Down 1.2%

Shares of GMED opened at $73.61 on Friday. The stock has a market capitalization of $9.88 billion, a P/E ratio of 18.83, a P/E/G ratio of 1.20 and a beta of 0.95. Globus Medical, Inc. has a twelve month low of $54.15 and a twelve month high of $101.40. The company has a 50 day moving average of $80.52 and a 200-day moving average of $83.89.

Globus Medical (NYSE:GMED – Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The medical device company reported $1.34 EPS for the quarter, topping analysts’ consensus estimates of $1.10 by $0.24. The business had revenue of $789.61 million for the quarter, compared to analyst estimates of $782.88 million. Globus Medical had a net margin of 17.02% and a return on equity of 14.57%. The firm’s revenue for the quarter was up 5.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.86 earnings per share. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. On average, sell-side analysts anticipate that Globus Medical, Inc. will post 4.99 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have issued reports on the company. Truist Financial decreased their target price on Globus Medical from $115.00 to $100.00 and set a “buy” rating for the company in a research note on Thursday, July 16th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Globus Medical in a research report on Monday, July 13th. Wells Fargo & Company cut their price objective on Globus Medical from $103.00 to $99.00 and set an “overweight” rating on the stock in a report on Friday, August 7th. BMO Capital Markets started coverage on Globus Medical in a research report on Wednesday, July 8th. They issued an “outperform” rating and a $94.00 price objective for the company. Finally, Royal Bank Of Canada decreased their price objective on Globus Medical from $120.00 to $115.00 and set an “outperform” rating for the company in a research report on Monday, July 13th. Three research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $101.77.

Check Out Our Latest Stock Analysis on GMED

Globus Medical Company Profile

(Free Report)

Globus Medical, Inc (NYSE: GMED) is a medical device company that develops, manufactures and markets musculoskeletal solutions for surgeons, hospitals and patients. Its primary focus is spinal surgery, supported by a portfolio of implants, instruments and enabling technologies designed to assist with procedures involving the cervical, thoracic and lumbar spine.

The company’s products include spinal fusion systems, interbody devices, deformity correction systems, biologics and surgical instruments.